usstocks Huatai Securities

CSI Intelligent Financial Information Hengtian Hailong (000677) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 277 million yuan, a year-on-year increase of 15.59%; net profit attributable to the parent company was 10.4447 million yuan, a year-on-year increase of 14.06%; non-net profit after deducting 9.8088 million yuan, a year-on-year increase of 7.37%; generated from operating activities Net cash flow was 39.4949 million yuan, a year-on-year decrease of 23.52%; during the reporting period, Hengtian Hailong\’s basic earnings per share was 0.0121 yuan, and the weighted average return on net assets was 2.24%.

Senhe Shares (301056) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 184 million yuan, a year-on-year increase of 43.47%; net profit attributable to the parent company was 28.5033 million yuan, a year-on-year increase of 170.64%; non-net profit after deducting 28.3691 million yuan, a year-on-year increase of 171.07%; generated from operating activities Net cash flow was -19.0282 million yuan, compared with 31.0244 million yuan in the same period last year; during the reporting period, Senhe\’s basic earnings per share was 0.1068 yuan, and the weighted average return on net assets was 3.40%.

Longgao Shares (605086) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 66.7652 million yuan, a year-on-year increase of 3.22%; net profit attributable to the parent company was 24.7442 million yuan, a year-on-year increase of 11.33%; non-net profit after deducting 22.8940 million yuan, a year-on-year increase of 2.15%; generated from operating activities Net cash flow was 41.1977 million yuan, a year-on-year increase of 9.41%; during the reporting period, Longgao\’s basic earnings per share was 0.19 yuan, and the weighted average return on net assets was 2.07%.

CSI Intelligent Financial Information Inner Mongolia Xinhua (603230) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 559 million yuan, a year-on-year increase of 8.00%; net profit attributable to the parent company was 128 million yuan, a year-on-year decrease of 9.81%; non-net profit after deducting 112 million yuan, a year-on-year decrease of 19.21%; generated from operating activities Net cash flow was -217 million yuan, compared with -120 million yuan in the same period last year; during the reporting period, Inner Mongolia Xinhua\’s basic earnings per share was 0.36 yuan, and the weighted average return on net assets was 4.86%.

For stock trading, please read Jin Qilin analyst research reports. They are authoritative, professional, timely and comprehensive, helping you to tap potential theme opportunities! Source: Financial Investment News Financial Investment News reporter Chen Yuhe After Zhifei Biotechnology (300122), the “vaccine brother”, released its 2023 annual report, its stock price continued to fall. Some market participants attributed its falling stock price to its high reliance on foreign supplies. Business is linked to the gradually revealed decline in performance. In recent years, the vaccine market has been changing. On the one hand, the once \”hot-selling\” nine-price HPV vaccine is no longer hard to find. On the other hand, various good news about the domestically produced nine-price HPV vaccine continue to spread, attracting a lot of attention. Institutions pay great attention to its listing process. Zhifei Bio\’s growth capability indicators Zhi Fei Bio\’s stock price continues to fall. The annual report shows that in 2023, Zhi Fei Bio\’s operating income was 52.918 billion yuan, a year-on-year increase of 38.3%; it achieved net profit attributable to the parent company of 8.07 billion yuan, a…